Loading…
Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer
Non-small cell lung cancer (NSCLC) remains the most common cause of cancer related death worldwide. Tumor-infiltrating macrophages are believed to play an important role in growth, progression, and metastasis of tumors. In NSCLC, the role of macrophages remains controversial; therefore, we aimed to...
Saved in:
| Published in: | BMC immunology 2018-01, Vol.19 (1), p.3-3, Article 3 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c660t-dca43195b16c42a8304a3d0c9e0811f8f226b5ceecff2e0389352c8c5d78c5d03 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c660t-dca43195b16c42a8304a3d0c9e0811f8f226b5ceecff2e0389352c8c5d78c5d03 |
| container_end_page | 3 |
| container_issue | 1 |
| container_start_page | 3 |
| container_title | BMC immunology |
| container_volume | 19 |
| creator | Jackute, Jurgita Zemaitis, Marius Pranys, Darius Sitkauskiene, Brigita Miliauskas, Skaidrius Vaitkiene, Simona Sakalauskas, Raimundas |
| description | Non-small cell lung cancer (NSCLC) remains the most common cause of cancer related death worldwide. Tumor-infiltrating macrophages are believed to play an important role in growth, progression, and metastasis of tumors. In NSCLC, the role of macrophages remains controversial; therefore, we aimed to evaluate the distribution of macrophages (M1 and M2) in tumor islets and stroma and to analyze their relations to patients' survival.
Lung tissue specimens from 80 NSCLC patients who underwent surgical resection for NSCLC (pathological stage I-III) and 16 control group subjects who underwent surgery because of recurrent spontaneous pneumothorax were analyzed. Immunohistochemical double staining of CD68/iNOS (markers for M1 macrophages) and CD68/CD163 (markers for M2 macrophages) was performed and evaluated in a blinded manner. The numbers of M1 and M2 macrophages in tumor islets and stroma were counted manually.
Predominant infiltration of M1 and M2 macrophages was observed in the tumor stroma compared with the tumor islets. M2 macrophages predominated over M1 macrophages in the tumor tissue. Tumor islets-infiltrating M1 macrophages and the number of total tumor-infiltrating M2 macrophages were independent predictors of patients survival: high infiltration of M1 macrophages in tumor islets was associated with increased overall survival in NSCLC (P |
| doi_str_mv | 10.1186/s12865-018-0241-4 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a0260ff5118648afb9ddd50c07765b24</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A546394503</galeid><doaj_id>oai_doaj_org_article_a0260ff5118648afb9ddd50c07765b24</doaj_id><sourcerecordid>A546394503</sourcerecordid><originalsourceid>FETCH-LOGICAL-c660t-dca43195b16c42a8304a3d0c9e0811f8f226b5ceecff2e0389352c8c5d78c5d03</originalsourceid><addsrcrecordid>eNptkl1v1SAcxhujcXP6AbwxJN7oRSd_KJTemCzz7SRbTHy5JpRCx9LCEVpfvr1wzpw7xpBAA7_nKTx5quop4FMAwV8lIIKzGoOoMWmgbu5Vx9C0UBNoyf0730fVo5SuMYZWEPGwOiId5dBBe1z9eOPSEl2_Li54FCy6BKT8gC4JmpWOYXulRpOQ82hZ5xCRS5NZ0g7JujCrchTNpHb6JaBtDKMPyaVi5oOv06ymCWmTp2n1I9LKaxMfVw-smpJ5crOeVF_fvf1y_qG--Ph-c352UWvO8VIPWjUUOtYD1w1RguJG0QHrzmABYIUlhPdMG6OtJQZT0VFGtNBsaMuE6Um12fsOQV3LbXSzir9kUE7uNkIcpYqL05ORChOOrWUl2kYo23fDMDCscdty1pMme73ee23XfjaDNn6JajowPTzx7kqO4btkrQAK5TIvbgxi-LaatMjZpZKM8iasSULXYcFoxwr6_B_0OqzR56gkYUxgjjkjf6lR5Qc4b0P-ry6m8ow1nHZNtsrU6X-oPAYzOx28sS7vHwheHggys5ify6jWlOTm86dDFvZsLktK0djbPADLEqXct1TmlsrSUlmCfHY3yFvFn1rS3_tF4I0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2558060652</pqid></control><display><type>article</type><title>Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer</title><source>PubMed (Medline)</source><source>Publicly Available Content (ProQuest)</source><creator>Jackute, Jurgita ; Zemaitis, Marius ; Pranys, Darius ; Sitkauskiene, Brigita ; Miliauskas, Skaidrius ; Vaitkiene, Simona ; Sakalauskas, Raimundas</creator><creatorcontrib>Jackute, Jurgita ; Zemaitis, Marius ; Pranys, Darius ; Sitkauskiene, Brigita ; Miliauskas, Skaidrius ; Vaitkiene, Simona ; Sakalauskas, Raimundas</creatorcontrib><description>Non-small cell lung cancer (NSCLC) remains the most common cause of cancer related death worldwide. Tumor-infiltrating macrophages are believed to play an important role in growth, progression, and metastasis of tumors. In NSCLC, the role of macrophages remains controversial; therefore, we aimed to evaluate the distribution of macrophages (M1 and M2) in tumor islets and stroma and to analyze their relations to patients' survival.
Lung tissue specimens from 80 NSCLC patients who underwent surgical resection for NSCLC (pathological stage I-III) and 16 control group subjects who underwent surgery because of recurrent spontaneous pneumothorax were analyzed. Immunohistochemical double staining of CD68/iNOS (markers for M1 macrophages) and CD68/CD163 (markers for M2 macrophages) was performed and evaluated in a blinded manner. The numbers of M1 and M2 macrophages in tumor islets and stroma were counted manually.
Predominant infiltration of M1 and M2 macrophages was observed in the tumor stroma compared with the tumor islets. M2 macrophages predominated over M1 macrophages in the tumor tissue. Tumor islets-infiltrating M1 macrophages and the number of total tumor-infiltrating M2 macrophages were independent predictors of patients survival: high infiltration of M1 macrophages in tumor islets was associated with increased overall survival in NSCLC (P < 0.05); high infiltration of total M2 macrophages in tumor (islets and stroma) was associated with reduced overall survival in NSCLC (P < 0.05).
This study demonstrated that high infiltration of M1 macrophages in the tumor islets and low infiltration of total tumor-infiltrating M2 macrophages were associated with improved NSCLC patients' survival.
ClinicalTrials.gov NCT01955343 , registered on September 27, 2013.</description><identifier>ISSN: 1471-2172</identifier><identifier>EISSN: 1471-2172</identifier><identifier>DOI: 10.1186/s12865-018-0241-4</identifier><identifier>PMID: 29361917</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Aged ; Analysis ; Antigens, CD - immunology ; Antigens, CD - metabolism ; Antigens, Differentiation, Myelomonocytic - immunology ; Antigens, Differentiation, Myelomonocytic - metabolism ; Cancer metastasis ; Cancer patients ; Carcinoma, Non-Small-Cell Lung - immunology ; Carcinoma, Non-Small-Cell Lung - metabolism ; Carcinoma, Non-Small-Cell Lung - pathology ; CD163 antigen ; Chronic obstructive pulmonary disease ; Clinical trials ; Connective tissue ; Cytokines ; Development and progression ; Disease ; Female ; Health aspects ; Humans ; Infiltration ; Kaplan-Meier Estimate ; Lung - immunology ; Lung - metabolism ; Lung - pathology ; Lung cancer ; Lung Neoplasms - immunology ; Lung Neoplasms - metabolism ; Lung Neoplasms - pathology ; Macrophages ; Macrophages - classification ; Macrophages - immunology ; Macrophages - metabolism ; Male ; Medical prognosis ; Metastases ; Metastasis ; Middle Aged ; Monoclonal antibodies ; Nitric Oxide Synthase Type II - immunology ; Nitric Oxide Synthase Type II - metabolism ; Nitric-oxide synthase ; Non-small cell lung cancer ; Non-small cell lung carcinoma ; Patients ; Pneumothorax ; Prognosis ; Receptors, Cell Surface - immunology ; Receptors, Cell Surface - metabolism ; Small cell lung carcinoma ; Smoking ; Stroma ; Thoracic surgery ; Tumor necrosis factor-TNF ; Tumors ; Young Adult</subject><ispartof>BMC immunology, 2018-01, Vol.19 (1), p.3-3, Article 3</ispartof><rights>COPYRIGHT 2018 BioMed Central Ltd.</rights><rights>2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s). 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c660t-dca43195b16c42a8304a3d0c9e0811f8f226b5ceecff2e0389352c8c5d78c5d03</citedby><cites>FETCH-LOGICAL-c660t-dca43195b16c42a8304a3d0c9e0811f8f226b5ceecff2e0389352c8c5d78c5d03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781310/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2558060652?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25733,27903,27904,36991,36992,44569,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29361917$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jackute, Jurgita</creatorcontrib><creatorcontrib>Zemaitis, Marius</creatorcontrib><creatorcontrib>Pranys, Darius</creatorcontrib><creatorcontrib>Sitkauskiene, Brigita</creatorcontrib><creatorcontrib>Miliauskas, Skaidrius</creatorcontrib><creatorcontrib>Vaitkiene, Simona</creatorcontrib><creatorcontrib>Sakalauskas, Raimundas</creatorcontrib><title>Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer</title><title>BMC immunology</title><addtitle>BMC Immunol</addtitle><description>Non-small cell lung cancer (NSCLC) remains the most common cause of cancer related death worldwide. Tumor-infiltrating macrophages are believed to play an important role in growth, progression, and metastasis of tumors. In NSCLC, the role of macrophages remains controversial; therefore, we aimed to evaluate the distribution of macrophages (M1 and M2) in tumor islets and stroma and to analyze their relations to patients' survival.
Lung tissue specimens from 80 NSCLC patients who underwent surgical resection for NSCLC (pathological stage I-III) and 16 control group subjects who underwent surgery because of recurrent spontaneous pneumothorax were analyzed. Immunohistochemical double staining of CD68/iNOS (markers for M1 macrophages) and CD68/CD163 (markers for M2 macrophages) was performed and evaluated in a blinded manner. The numbers of M1 and M2 macrophages in tumor islets and stroma were counted manually.
Predominant infiltration of M1 and M2 macrophages was observed in the tumor stroma compared with the tumor islets. M2 macrophages predominated over M1 macrophages in the tumor tissue. Tumor islets-infiltrating M1 macrophages and the number of total tumor-infiltrating M2 macrophages were independent predictors of patients survival: high infiltration of M1 macrophages in tumor islets was associated with increased overall survival in NSCLC (P < 0.05); high infiltration of total M2 macrophages in tumor (islets and stroma) was associated with reduced overall survival in NSCLC (P < 0.05).
This study demonstrated that high infiltration of M1 macrophages in the tumor islets and low infiltration of total tumor-infiltrating M2 macrophages were associated with improved NSCLC patients' survival.
ClinicalTrials.gov NCT01955343 , registered on September 27, 2013.</description><subject>Adult</subject><subject>Aged</subject><subject>Analysis</subject><subject>Antigens, CD - immunology</subject><subject>Antigens, CD - metabolism</subject><subject>Antigens, Differentiation, Myelomonocytic - immunology</subject><subject>Antigens, Differentiation, Myelomonocytic - metabolism</subject><subject>Cancer metastasis</subject><subject>Cancer patients</subject><subject>Carcinoma, Non-Small-Cell Lung - immunology</subject><subject>Carcinoma, Non-Small-Cell Lung - metabolism</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>CD163 antigen</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Clinical trials</subject><subject>Connective tissue</subject><subject>Cytokines</subject><subject>Development and progression</subject><subject>Disease</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Infiltration</subject><subject>Kaplan-Meier Estimate</subject><subject>Lung - immunology</subject><subject>Lung - metabolism</subject><subject>Lung - pathology</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - immunology</subject><subject>Lung Neoplasms - metabolism</subject><subject>Lung Neoplasms - pathology</subject><subject>Macrophages</subject><subject>Macrophages - classification</subject><subject>Macrophages - immunology</subject><subject>Macrophages - metabolism</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Nitric Oxide Synthase Type II - immunology</subject><subject>Nitric Oxide Synthase Type II - metabolism</subject><subject>Nitric-oxide synthase</subject><subject>Non-small cell lung cancer</subject><subject>Non-small cell lung carcinoma</subject><subject>Patients</subject><subject>Pneumothorax</subject><subject>Prognosis</subject><subject>Receptors, Cell Surface - immunology</subject><subject>Receptors, Cell Surface - metabolism</subject><subject>Small cell lung carcinoma</subject><subject>Smoking</subject><subject>Stroma</subject><subject>Thoracic surgery</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>1471-2172</issn><issn>1471-2172</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkl1v1SAcxhujcXP6AbwxJN7oRSd_KJTemCzz7SRbTHy5JpRCx9LCEVpfvr1wzpw7xpBAA7_nKTx5quop4FMAwV8lIIKzGoOoMWmgbu5Vx9C0UBNoyf0730fVo5SuMYZWEPGwOiId5dBBe1z9eOPSEl2_Li54FCy6BKT8gC4JmpWOYXulRpOQ82hZ5xCRS5NZ0g7JujCrchTNpHb6JaBtDKMPyaVi5oOv06ymCWmTp2n1I9LKaxMfVw-smpJ5crOeVF_fvf1y_qG--Ph-c352UWvO8VIPWjUUOtYD1w1RguJG0QHrzmABYIUlhPdMG6OtJQZT0VFGtNBsaMuE6Um12fsOQV3LbXSzir9kUE7uNkIcpYqL05ORChOOrWUl2kYo23fDMDCscdty1pMme73ee23XfjaDNn6JajowPTzx7kqO4btkrQAK5TIvbgxi-LaatMjZpZKM8iasSULXYcFoxwr6_B_0OqzR56gkYUxgjjkjf6lR5Qc4b0P-ry6m8ow1nHZNtsrU6X-oPAYzOx28sS7vHwheHggys5ify6jWlOTm86dDFvZsLktK0djbPADLEqXct1TmlsrSUlmCfHY3yFvFn1rS3_tF4I0</recordid><startdate>20180124</startdate><enddate>20180124</enddate><creator>Jackute, Jurgita</creator><creator>Zemaitis, Marius</creator><creator>Pranys, Darius</creator><creator>Sitkauskiene, Brigita</creator><creator>Miliauskas, Skaidrius</creator><creator>Vaitkiene, Simona</creator><creator>Sakalauskas, Raimundas</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180124</creationdate><title>Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer</title><author>Jackute, Jurgita ; Zemaitis, Marius ; Pranys, Darius ; Sitkauskiene, Brigita ; Miliauskas, Skaidrius ; Vaitkiene, Simona ; Sakalauskas, Raimundas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c660t-dca43195b16c42a8304a3d0c9e0811f8f226b5ceecff2e0389352c8c5d78c5d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Analysis</topic><topic>Antigens, CD - immunology</topic><topic>Antigens, CD - metabolism</topic><topic>Antigens, Differentiation, Myelomonocytic - immunology</topic><topic>Antigens, Differentiation, Myelomonocytic - metabolism</topic><topic>Cancer metastasis</topic><topic>Cancer patients</topic><topic>Carcinoma, Non-Small-Cell Lung - immunology</topic><topic>Carcinoma, Non-Small-Cell Lung - metabolism</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>CD163 antigen</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Clinical trials</topic><topic>Connective tissue</topic><topic>Cytokines</topic><topic>Development and progression</topic><topic>Disease</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Infiltration</topic><topic>Kaplan-Meier Estimate</topic><topic>Lung - immunology</topic><topic>Lung - metabolism</topic><topic>Lung - pathology</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - immunology</topic><topic>Lung Neoplasms - metabolism</topic><topic>Lung Neoplasms - pathology</topic><topic>Macrophages</topic><topic>Macrophages - classification</topic><topic>Macrophages - immunology</topic><topic>Macrophages - metabolism</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Nitric Oxide Synthase Type II - immunology</topic><topic>Nitric Oxide Synthase Type II - metabolism</topic><topic>Nitric-oxide synthase</topic><topic>Non-small cell lung cancer</topic><topic>Non-small cell lung carcinoma</topic><topic>Patients</topic><topic>Pneumothorax</topic><topic>Prognosis</topic><topic>Receptors, Cell Surface - immunology</topic><topic>Receptors, Cell Surface - metabolism</topic><topic>Small cell lung carcinoma</topic><topic>Smoking</topic><topic>Stroma</topic><topic>Thoracic surgery</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jackute, Jurgita</creatorcontrib><creatorcontrib>Zemaitis, Marius</creatorcontrib><creatorcontrib>Pranys, Darius</creatorcontrib><creatorcontrib>Sitkauskiene, Brigita</creatorcontrib><creatorcontrib>Miliauskas, Skaidrius</creatorcontrib><creatorcontrib>Vaitkiene, Simona</creatorcontrib><creatorcontrib>Sakalauskas, Raimundas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jackute, Jurgita</au><au>Zemaitis, Marius</au><au>Pranys, Darius</au><au>Sitkauskiene, Brigita</au><au>Miliauskas, Skaidrius</au><au>Vaitkiene, Simona</au><au>Sakalauskas, Raimundas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer</atitle><jtitle>BMC immunology</jtitle><addtitle>BMC Immunol</addtitle><date>2018-01-24</date><risdate>2018</risdate><volume>19</volume><issue>1</issue><spage>3</spage><epage>3</epage><pages>3-3</pages><artnum>3</artnum><issn>1471-2172</issn><eissn>1471-2172</eissn><abstract>Non-small cell lung cancer (NSCLC) remains the most common cause of cancer related death worldwide. Tumor-infiltrating macrophages are believed to play an important role in growth, progression, and metastasis of tumors. In NSCLC, the role of macrophages remains controversial; therefore, we aimed to evaluate the distribution of macrophages (M1 and M2) in tumor islets and stroma and to analyze their relations to patients' survival.
Lung tissue specimens from 80 NSCLC patients who underwent surgical resection for NSCLC (pathological stage I-III) and 16 control group subjects who underwent surgery because of recurrent spontaneous pneumothorax were analyzed. Immunohistochemical double staining of CD68/iNOS (markers for M1 macrophages) and CD68/CD163 (markers for M2 macrophages) was performed and evaluated in a blinded manner. The numbers of M1 and M2 macrophages in tumor islets and stroma were counted manually.
Predominant infiltration of M1 and M2 macrophages was observed in the tumor stroma compared with the tumor islets. M2 macrophages predominated over M1 macrophages in the tumor tissue. Tumor islets-infiltrating M1 macrophages and the number of total tumor-infiltrating M2 macrophages were independent predictors of patients survival: high infiltration of M1 macrophages in tumor islets was associated with increased overall survival in NSCLC (P < 0.05); high infiltration of total M2 macrophages in tumor (islets and stroma) was associated with reduced overall survival in NSCLC (P < 0.05).
This study demonstrated that high infiltration of M1 macrophages in the tumor islets and low infiltration of total tumor-infiltrating M2 macrophages were associated with improved NSCLC patients' survival.
ClinicalTrials.gov NCT01955343 , registered on September 27, 2013.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>29361917</pmid><doi>10.1186/s12865-018-0241-4</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2172 |
| ispartof | BMC immunology, 2018-01, Vol.19 (1), p.3-3, Article 3 |
| issn | 1471-2172 1471-2172 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_a0260ff5118648afb9ddd50c07765b24 |
| source | PubMed (Medline); Publicly Available Content (ProQuest) |
| subjects | Adult Aged Analysis Antigens, CD - immunology Antigens, CD - metabolism Antigens, Differentiation, Myelomonocytic - immunology Antigens, Differentiation, Myelomonocytic - metabolism Cancer metastasis Cancer patients Carcinoma, Non-Small-Cell Lung - immunology Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - pathology CD163 antigen Chronic obstructive pulmonary disease Clinical trials Connective tissue Cytokines Development and progression Disease Female Health aspects Humans Infiltration Kaplan-Meier Estimate Lung - immunology Lung - metabolism Lung - pathology Lung cancer Lung Neoplasms - immunology Lung Neoplasms - metabolism Lung Neoplasms - pathology Macrophages Macrophages - classification Macrophages - immunology Macrophages - metabolism Male Medical prognosis Metastases Metastasis Middle Aged Monoclonal antibodies Nitric Oxide Synthase Type II - immunology Nitric Oxide Synthase Type II - metabolism Nitric-oxide synthase Non-small cell lung cancer Non-small cell lung carcinoma Patients Pneumothorax Prognosis Receptors, Cell Surface - immunology Receptors, Cell Surface - metabolism Small cell lung carcinoma Smoking Stroma Thoracic surgery Tumor necrosis factor-TNF Tumors Young Adult |
| title | Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A58%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Distribution%20of%20M1%20and%20M2%20macrophages%20in%20tumor%20islets%20and%20stroma%20in%20relation%20to%20prognosis%20of%20non-small%20cell%20lung%20cancer&rft.jtitle=BMC%20immunology&rft.au=Jackute,%20Jurgita&rft.date=2018-01-24&rft.volume=19&rft.issue=1&rft.spage=3&rft.epage=3&rft.pages=3-3&rft.artnum=3&rft.issn=1471-2172&rft.eissn=1471-2172&rft_id=info:doi/10.1186/s12865-018-0241-4&rft_dat=%3Cgale_doaj_%3EA546394503%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c660t-dca43195b16c42a8304a3d0c9e0811f8f226b5ceecff2e0389352c8c5d78c5d03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2558060652&rft_id=info:pmid/29361917&rft_galeid=A546394503&rfr_iscdi=true |